Marchais S J, Guerin A P, London G M
Department of Neurology, Manhes Hospital, Fleury-Mérogis, France.
Drugs. 1992;44 Suppl 1:119-22. doi: 10.2165/00003495-199200441-00022.
A progressive rise in arterial calcium content is the most characteristic age-associated alteration in the arterial wall and the decisive factor in arteriosclerotic degeneration. Experimental studies have demonstrated that calcium antagonists can prevent or retard the development of arterial calcinosis associated with vitamin D overload, hypertension or alloxan-induced diabetes. Although similar effects are more difficult to observe in humans, they have been demonstrated in patients with coronary artery disease and in patients with end-stage renal disease, which is characterised by an acceleration of the normal arterial aging process.
动脉钙含量的逐渐升高是动脉壁最典型的与年龄相关的改变，也是动脉硬化性退变的决定性因素。实验研究表明，钙拮抗剂可预防或延缓与维生素D过量、高血压或四氧嘧啶诱导的糖尿病相关的动脉钙化发展。虽然在人类中更难观察到类似的效果，但在冠状动脉疾病患者和终末期肾病患者中已得到证实，终末期肾病的特点是正常动脉衰老过程加速。
